Citi initiates coverage of Maze Therapeutics with Buy rating
Tweet
Share
E-mailGet Alerts MAZE Hot Sheet
Price: $28.38 --0%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 30
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 30
Join SI Premium – FREE
(Updated - September 23, 2026 5:02 AM EDT)
Citi analyst Eric Joseph initiated coverage of Maze Therapeutics (NASDAQ: MAZE) with an Buy rating and a 12-month price target of $50.00
Joseph cited the company's lead program MZE829, describing it as exhibiting "a best-in-class oral APOL1 inhibitor profile for the treatment of AMKD," and noted that pipeline candidate MZE782 is a potential treatment for PKU.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi reiterates buy rating on On Holding AG with $55 target
- Mosaic Minerals closes $592K private placement, plans drilling
- HUHUTECH posts 8.6% revenue gain as net loss nearly doubles
Create E-mail Alert Related Categories
New CoverageRelated Entities
Citi, CIBC, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
